Longitudinal biomarker evaluation in Fabry disease patients receiving lentivirus-mediated gene therapy

Abstract

Aim: In 2016, a team of Canadian researchers initiated the world’s first gene therapy clinical trial for Fabry disease. The study, aiming to determine the safety and toxicity of lentivirus α-galactosidase A transduced autologous CD34+ cells in adult males with Fabry disease (n = 5), was conducted at three Canadian centers. The objective of the present work was to evaluate a profile of Fabry disease-related biomarkers in five participants during a 5-year surveillance period, as part of the evaluation of this novel therapy.

Methods: Sixteen globotriaosylceramide (Gb₃) isoforms and eight globotriaosylsphingosine (lyso-Gb₃) analogues were measured by LC-MS/MS in plasma and urine at numerous time points before and after gene therapy. Plasma and peripheral blood leukocyte α-galactosidase A activity were also measured.

Results: Levels of urine and plasma lyso-Gb₃ and analogues, and urine Gb₃ were lower after gene therapy and while treated with enzyme replacement therapy (ERT) compared to baseline (before gene therapy) in participants treated with ERT only. Three participants chose to cease ERT treatment at some point after gene therapy. Two of these patients had lower levels of urine and plasma lyso-Gb₃ and analogues compared to baseline, whereas one participant had higher levels of these biomarkers compared to baseline. An increase in urine Gb₃ was observed when ERT treatment ceased after gene therapy (P < 0.05) in all three participants.

Conclusion: The evaluation of this complete glycosphingolipid biomarker profile was useful in monitoring the biochemical response to gene therapy in this cohort of five patients with Fabry disease.

Keywords

Fabry disease / biomarkers / gene therapy / globotriaosylceramide / globotriaosylsphingosine / analogues

References

[1] Kok K,Boot RG,Aerts JMFG.Fabry disease: molecular basis, pathophysiology, diagnostics and potential therapeutic directions.Biomolecules2021;11:271 PMCID:PMC7918333

[2] Ryckman AE,Walia JS.Metabolism of glycosphingolipids and their role in the pathophysiology of lysosomal storage disorders.Int J Mol Sci2020;21:6881 PMCID:PMC7555265

[3] Perretta F,Jaurretche S.Major organic involvement in women with fabry disease in argentina.Sci World J2018;2018:6515613 PMCID:PMC5987241

[4] Ramaswami U,Parini R.Clinical manifestations of Fabry disease in children: data from the Fabry outcome survey.Acta Paediatr2006;95:86-92

[5] Caputo F,Galdi A.Gastrointestinal involvement in anderson-Fabry disease: a narrative review.Int J Environ Res Public Health2021;18:3320 PMCID:PMC8005161

[6] Pieroni M,Arbustini E.Cardiac involvement in Fabry disease: JACC review topic of the week.J Am Coll Cardiol2021;77:922-36

[7] Silva CAB,Dos Reis MA,Barreto FC.Renal manifestations of Fabry disease: a narrative review.Can J Kidney Health Dis2021;8:2054358120985627 PMCID:PMC7960898

[8] Mishra V,Gandhi AB.Stroke and Fabry disease: a review of literature.Cureus2020;12:e12083 PMCID:PMC7805529

[9] Germain DP.Fabry disease.Orphanet J Rare Dis2010;5:30 PMCID:PMC3009617

[10] Kant S.Therapeutic advances in Fabry disease: the future awaits.Biomed Pharmacother2020;131:110779

[11] Lenders M.Fabry disease: the current treatment landscape.Drugs2021;81:635-45 PMCID:PMC8102455

[12] EMA. Elfabrio. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/elfabrio [Last accessed on 21 Jun 2024]

[13] FDA. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761161s000lbl.pdf [Last accessed on 21 Jun 2024]

[14] McCafferty EH.Migalastat: a review in Fabry disease.Drugs2019;79:543-54

[15] Felis A,Kraus A,Wallace E.Current and investigational therapeutics for Fabry disease.Kidney Int Rep2020;5:407-13 PMCID:PMC7136345

[16] Khan A,Huang J.Lentivirus-mediated gene therapy for Fabry disease.Nat Commun2021;12:1178 PMCID:PMC7907075

[17] Simonetta I,Daidone M.Biomarkers in anderson-Fabry disease.Int J Mol Sci2020;21:8080 PMCID:PMC7662984

[18] Carnicer-Cáceres C,Cea-Arestin C.Biomarkers in Fabry disease. Implications for clinical diagnosis and follow-up.J Clin Med2021;10:1664 PMCID:PMC8068937

[19] Bengtsson BA,Hollak C,FeldtRasmussen U.Enzyme replacement in anderson-Fabry disease.Lancet2003;361:352

[20] Schiffmann R,Austin HA 3rd.Enzyme replacement therapy in Fabry disease: a randomized controlled trial.JAMA2001;285:2743-9

[21] Eng CM,Wilcox WR.Safety and efficacy of recombinant human alpha-galactosidase a replacement therapy in Fabry’s disease.N Engl J Med2001;345:9-16

[22] Aerts JM,Kuiper S.Elevated globotriaosylsphingosine is a hallmark of Fabry disease.Proc Natl Acad Sci USA2008;105:2812-7 PMCID:PMC2268542

[23] Dupont FO,Boutin M.A metabolomic study reveals novel plasma lyso-Gb3 analogs as Fabry disease biomarkers.Curr Med Chem2013;20:280-8

[24] Auray-Blais C,Gagnon R,Lavoie P.Urinary globotriaosylsphingosine-related biomarkers for Fabry disease targeted by metabolomics.Anal Chem2012;84:2745-53

[25] Manwaring V,Auray-Blais C.A metabolomic study to identify new globotriaosylceramide-related biomarkers in the plasma of Fabry disease patients.Anal Chem2013;85:9039-48

[26] Auray-Blais C.Novel Gb3 isoforms detected in urine of Fabry disease patients: a metabolomic study.Curr Med Chem2012;19:3241-52

[27] Auray-Blais C,Boutin M.Biomarkers associated with clinical manifestations in Fabry disease patients with a late-onset cardiac variant mutation.Clin Chim Acta2017;466:185-93

[28] Auray-Blais C,Ramaswami U.Urinary biomarker investigation in children with Fabry disease using tandem mass spectrometry.Clin Chim Acta2015;438:195-204

[29] Lavoie P,Auray-Blais C.Multiplex analysis of novel urinary lyso-Gb3-related biomarkers for Fabry disease by tandem mass spectrometry.Anal Chem2013;85:1743-52

[30] Finkelstein JD.Metabolic regulatory properties of S-adenosylmethionine and S-adenosylhomocysteine.Clin Chem Lab Med2007;45:1694-9

[31] Lohse B,Kristensen LH.Inhibitors of histone demethylases.Bioorg Med Chem2011;19:3625-36

[32] Bai HW,Yu J.Biochemical and molecular modeling studies of the O-methylation of various endogenous and exogenous catechol substrates catalyzed by recombinant human soluble and membrane-bound catechol-O-methyltransferases.Chem Res Toxicol2007;20:1409-25

[33] Patti GJ,Shriver LP.Metabolomics implicates altered sphingolipids in chronic pain of neuropathic origin.Nat Chem Biol2012;8:232-4 PMCID:PMC3567618

[34] Abaoui M,Lavoie P.High-risk screening of Fabry disease: analysis of fifteen urinary methylated and non-methylated Gb₃ isoforms using tandem mass spectrometry.Curr Protoc Hum Genet2016;91:17.24.1-11

[35] Abaoui M,Lavoie P.Tandem mass spectrometry multiplex analysis of methylated and non-methylated urinary Gb₃ isoforms in Fabry disease patients.Clin Chim Acta2016;452:191-8

[36] Lavoie P,Abaoui M.Fabry disease biomarkers: analysis of urinary lyso-Gb3 and seven related analogs using tandem mass spectrometry.Curr Protoc Hum Genet2016;90:17.22.1-12

[37] Boutin M,Abaoui M.Tandem mass spectrometry quantitation of lyso-Gb3 and six related analogs in plasma for Fabry disease patients.Curr Protoc Hum Genet2016;90:17.23.1-9

[38] Desnick RJ,Desnick SJ,Bernlohr RW.Fabry’s disease: enzymatic diagnosis of hemizygotes and heterozygotes. Alpha-galactosidase activities in plasma, serum, urine, and leukocytes.J Lab Clin Med1973;81:157-71.

[39] Thurberg BL,Colvin RB.Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy.Kidney Int2002;62:1933-46

[40] Chatterjee S,Pyeritz RE.Immunohistochemical localization of glycosphingolipid in urinary renal tubular cells in Fabry’s disease.Am J Clin Pathol1984;82:24-8

[41] Schiffmann R,Benigni A.Biomarkers of Fabry disease nephropathy.Clin J Am Soc Nephrol2010;5:360-4

[42] Fall B,Mauer M.Urinary podocyte loss is increased in patients with Fabry disease and correlates with clinical severity of Fabry nephropathy.PLoS One2016;11:e0168346 PMCID:PMC5161377

[43] Najafian B,Svarstad E,Oliveira JP.Accumulation of Globotriaosylceramide in podocytes in Fabry nephropathy is associated with progressive podocyte loss.J Am Soc Nephrol2020;31:865-75 PMCID:PMC7191924

[44] Shiga T,Namai Y,Sakuraba H.Comparative urinary globotriaosylceramide analysis by thin-layer chromatography-immunostaining and liquid chromatography-tandem mass spectrometry in patients with Fabry disease.Mol Genet Metab Rep2021;29:100804 PMCID:PMC8488402

[45] Moura AP,Deon M,Vargas CR.Investigation of correlation of urinary globotriaosylceramide (Gb₃) levels with markers of renal function in patients with Fabry disease.Clin Chim Acta2018;478:62-7

[46] Vedder AC,van Breemen MJ.The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels.J Inherit Metab Dis2007;30:68-78

[47] Nowak A,Hornemann T.Genotype, phenotype and disease severity reflected by serum LysoGb3 levels in patients with Fabry disease.Mol Genet Metab2018;123:148-53

[48] Nowak A,Sivasubramaniam V,Warnock DG.Lyso-Gb3 associates with adverse long-term outcome in patients with Fabry disease.J Med Genet2022;59:287-93 PMCID:PMC8867289

[49] Niemann M,Störk S.Gene mutations versus clinically relevant phenotypes: lyso-Gb3 defines Fabry disease.Circ Cardiovasc Genet2014;7:8-16

[50] Nikolaenko V,Mills K.Elucidating the toxic effect and disease mechanisms associated with Lyso-Gb3 in Fabry disease.Hum Mol Genet2023;32:2464-72 PMCID:PMC10360391

[51] Hwang AR,Woo CH.Lyso-globotriaosylsphingosine induces endothelial dysfunction via autophagy-dependent regulation of necroptosis.Korean J Physiol Pharmacol2023;27:231-40 PMCID:PMC10122999

[52] Sanchez-Niño MD,Carrasco S.Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy.Nephrol Dial Transplant2011;26:1797-802

[53] Choi L,Kopach O.The Fabry disease-associated lipid Lyso-Gb3 enhances voltage-gated calcium currents in sensory neurons and causes pain.Neurosci Lett2015;594:163-8 PMCID:PMC4411215

[54] van der Veen SJ,Hollak CEM.Early risk stratification for natural disease course in Fabry patients using plasma globotriaosylsphingosine levels.Clin J Am Soc Nephrol2023;18:1272-82 PMCID:PMC10578638

[55] Ouyang Y,Zhao Z.Globotriaosylsphingosine improves risk stratification of kidney progression in Fabry disease patients.Clin Chim Acta2024;556:117851

[56] Duro G,Cammarata G.Mutations in the GLA gene and LysoGb3: is it really anderson-Fabry disease?.Int J Mol Sci2018;19:3726 PMCID:PMC6320967

[57] Ferreira S,Boutin M.Variations in the GLA gene correlate with globotriaosylceramide and globotriaosylsphingosine analog levels in urine and plasma.Clin Chim Acta2015;447:96-104 PMCID:PMC4793778

[58] Germain DP,Barriales-Villa R.An expert consensus on practical clinical recommendations and guidance for patients with classic Fabry disease.Mol Genet Metab2022;137:49-61